产品
编 号：F138670
分子式：C11H12ClN5
分子量：249.7
分子式：C11H12ClN5
分子量：249.7
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
100mg
询价
询价
结构图
CAS No: 136-40-3
产品详情
生物活性：
Phenazopyridine hydrochlorideis a competitive SARM1 inhibitor, with IC50 145 μM. Phenazopyridine hydrochlorideis a TRPM8 antagonist. Phenazopyridine hydrochloride has a local anesthetic/analgesic effect. Phenazopyridine hydrochlorideis used to relieve painful symptoms of conditions such as cystitis and urethritis. Phenazopyridine hydrochloridecan promote neuronal differentiation and can also be used in the study of traumatic brain injury, peripheral neuropathy and neurodegenerative diseases.
体内研究：
Phenazopyridine (15 m/kg; 侧脑室注射; 一天一次连续 2 周) 通过促进 RPS23RG1 的表达来改善阿尔兹海默症 (AD) APP/PS1 小鼠的一些 AD 相关认知障碍和病理。Phenazopyridine (0.1-3 mg/kg; 静脉注射；单剂量) 能抑制 Sprague–Dawley 大鼠中机械敏感的 Aδ-纤维，而对 C-纤维无抑制作用。Animal Model:C57BL/6 mice model of Alzheimer's disease
Dosage:15 mg/kg
Administration:Intraperitoneal injection (i.p.); Once daily for 2 weeks
Result:Increased the RPS23RG1 levels in lungs, liver and kidneys of mice.
Animal Model:APP/PS1 mice model of Alzheimer's disease
Dosage:15 mg/kg
Administration:Intracerebroventricularly injection; Once daily for 2 weeks
Result:Significantly reduced amyloid plaques.Increased protein levels of RPS23RG1, PSD-95, and phosphorylated/inactivated GSK-3β, though without affecting levels of tau, phosphorylated tau, and p35.
体外研究：
Phenazopyridine (10-30 μM; 12 h) 在人 SHSY5Y 和小鼠 N2a 细胞中均增加了 RPS23RG1 的 mRNA 的表达。Phenazopyridine (5-50 μM; 2 分钟) 在 HEK293 细胞中以浓度依赖和可逆的方式抑制薄荷醇 ( 50 μM) 诱导的 TRPM8 反应，IC50 值为9.6 μM。Phenazopyridine hydrochloride(3 μM; 6 周) 在人胚胎干细胞中能促进神经元分化。
Phenazopyridine hydrochlorideis a competitive SARM1 inhibitor, with IC50 145 μM. Phenazopyridine hydrochlorideis a TRPM8 antagonist. Phenazopyridine hydrochloride has a local anesthetic/analgesic effect. Phenazopyridine hydrochlorideis used to relieve painful symptoms of conditions such as cystitis and urethritis. Phenazopyridine hydrochloridecan promote neuronal differentiation and can also be used in the study of traumatic brain injury, peripheral neuropathy and neurodegenerative diseases.
体内研究：
Phenazopyridine (15 m/kg; 侧脑室注射; 一天一次连续 2 周) 通过促进 RPS23RG1 的表达来改善阿尔兹海默症 (AD) APP/PS1 小鼠的一些 AD 相关认知障碍和病理。Phenazopyridine (0.1-3 mg/kg; 静脉注射；单剂量) 能抑制 Sprague–Dawley 大鼠中机械敏感的 Aδ-纤维，而对 C-纤维无抑制作用。Animal Model:C57BL/6 mice model of Alzheimer's disease
Dosage:15 mg/kg
Administration:Intraperitoneal injection (i.p.); Once daily for 2 weeks
Result:Increased the RPS23RG1 levels in lungs, liver and kidneys of mice.
Animal Model:APP/PS1 mice model of Alzheimer's disease
Dosage:15 mg/kg
Administration:Intracerebroventricularly injection; Once daily for 2 weeks
Result:Significantly reduced amyloid plaques.Increased protein levels of RPS23RG1, PSD-95, and phosphorylated/inactivated GSK-3β, though without affecting levels of tau, phosphorylated tau, and p35.
体外研究：
Phenazopyridine (10-30 μM; 12 h) 在人 SHSY5Y 和小鼠 N2a 细胞中均增加了 RPS23RG1 的 mRNA 的表达。Phenazopyridine (5-50 μM; 2 分钟) 在 HEK293 细胞中以浓度依赖和可逆的方式抑制薄荷醇 ( 50 μM) 诱导的 TRPM8 反应，IC50 值为9.6 μM。Phenazopyridine hydrochloride(3 μM; 6 周) 在人胚胎干细胞中能促进神经元分化。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备